MCC950
别名: CP-456773, CRID3
目录号:S8930 Purity: 99.8%
MCC950 (CP-456773, CRID3) 是一种有效的 NLRP3 (NOD-like receptor (NLR) family, pyrin domain-containing protein 3) 的选择性抑制剂,在BMDMs和HMDMs中对应的IC50值分别为7.5 nM和8.1 nM。
CAS: 210826-40-7
客户使用Selleck的MCC950发表文献109篇
- Cell, 2023 186(10):2144-2159.e22
- Cell Mol Immunol, 2022 19(8):925-943
- Int J Biol Sci, 2024 20(14):5695-5714
- Cell Death Dis, 2024 15(1):43
- Cell Prolif, 2024 e13720.
- Int J Nanomedicine, 2024 19:12675-12693
- J Transl Med, 2024 22(1):23
- J Transl Med, 2024 22(1):954
- J Transl Med, 2024 22(1):1139
- J Transl Med, 2024 22(1):497
- Cell Death Discov, 2024 10(1):122
- Ecotoxicol Environ Saf, 2024 272:116004
- Transl Psychiatry, 2024 14(1):166
- Immunology, 2024 10.1111/imm.13773
- Am J Pathol, 2024 S0002-9440(24)00116-0
- Int Immunopharmacol, 2024 143(Pt 2):113428
- Int J Mol Med, 2024 53(3)25
- Inflammation, 2024 10.1007/s10753-024-02178-0
- J Inflamm Res, 2024 17:6935-6954
- J Inflamm Res, 2024 17:1707-1720
- PLoS One, 2024 19(2):e0295837
- Brain Behav Immun, 2023 110:60-79
- Cell Rep Med, 2023 4(8):101129
- Gut Microbes, 2023 15(1):2192478
- EMBO J, 2023 42(9):e113490
- MedComm (2020), 2023 4(6):e447
- J Neuroinflammation, 2023 10.1186/s12974-023-02938-z
- J Neuroinflammation, 2023 20(1):148
- J Neuroinflammation, 2023 20(1):82
- Int J Biol Sci, 2023 19(6):1875-1893
- J Pharm Anal, 2023 13(9):999-1012
- Int J Nanomedicine, 2023 18:7505-7521
- Front Immunol, 2023 14:1128700
- Front Immunol, 2023 14:1174463
- Transplantation, 2023 107(11):2364-2376
- iScience, 2023 26(4):106523
- Biol Direct, 2023 18(1):29
- Acta Biochim Biophys Sin (Shanghai), 2023 55(3):460-471
- Front Cardiovasc Med, 2023 10:1126391
- Mol Med Rep, 2023 27(3)71
- Biotechnol Appl Biochem, 2023 10.1002/bab.2518
- Cancer Immunol Res, 2022 10(12):1542-1558
- J Neuroinflammation, 2022 19(1):308
- Am J Transplant, 2022 10.1111/ajt.16968
- Cell Rep, 2022 41(10):111742
- Cell Rep, 2022 38(11):110507
- Front Immunol, 2022 13:832458
- Ecotoxicol Environ Saf, 2022 244:114067
- Cells, 2022 11(1)134
- Cells, 2022 11(10)1630
- Commun Biol, 2022 5(1):618
- Int J Mol Sci, 2022 23(9)5078
- J Cell Physiol, 2022 10.1002/jcp.30663
- Front Pharmacol, 2022 13:877988
- Int Immunopharmacol, 2022 108:108757
- J Ethnopharmacol, 2022 296:115457
- Ann N Y Acad Sci, 2022 1508(1):92-104
- Chin Med, 2022 17(1):17
- Front Aging Neurosci, 2022 14:878484
- Cell Signal, 2022 93:110304
- Int J Biochem Cell Biol, 2022 149:106247
- Brain Res Bull, 2022 187:1-10
- Acta Biochim Biophys Sin (Shanghai), 2022 54(1):64-76
- Dis Markers, 2022 2022:2329904
- Genes (Basel), 2022 13(11)2133
- Free Radic Res, 2022 1-13
- J Dermatol, 2022 49(10):1037-1048
- PeerJ, 2022 10:e13799
- J Ginseng Res, 2022 46(5):700-709
- Kyoto University Research Information Repository, 2022 10.14989/doctor.r13497
- J Exp Med, 2021 218(9)e20202637
- EBioMedicine, 2021 75:103803
- Metabolism, 2021 118:154748
- J Neuroinflammation, 2021 18(1):66
- J Neuroinflammation, 2021 18(1):163
- Cell Death Dis, 2021 12(10):871
- Cell Death Dis, 2021 12(1):87
- EMBO Rep, 2021 e50743
- Elife, 2021 10e70938
- Biomed Pharmacother, 2021 143:112133
- Thromb Res, 2021 199:1-9
- Free Radic Biol Med, 2021 165:171-183
- Oxid Med Cell Longev, 2021 2021:9925561
- Front Immunol, 2021 12:753092
- Immunology, 2021 10.1111/imm.13402
- Glia, 2021 69(5):1268-1280
- Front Pharmacol, 2021 12:743086
- Int Immunopharmacol, 2021 99:107962
- Front Cell Dev Biol, 2021 9:779432
- Int J Mol Med, 2021 47(2):607-620
- J Cell Mol Med, 2021 10.1111/jcmm.16863
- Virulence, 2021 12(1):1362-1376
- Food Chem Toxicol, 2021 S0278-6915(21)00805-X
- J Neurotrauma, 2021 10.1089/neu.2020.7481
- Exp Dermatol, 2021 10.1111/exd.14432
- BMC Anesthesiol, 2021 21(1):104
- J Med Virol, 2020 10.1002/jmv.26329
- J Neuroinflammation, 2020 17(1):205
- Cell Death Dis, 2020 11(10):901
- Phytomedicine, 2020 80:153398
- J Dent Res, 2020 22034520933533
- Front Cell Dev Biol, 2020 8:608
- J Inflamm (Lond), 2020 17:22
- Inflammation, 2020 10.1007/s10753-020-01289-8
- Cell Signal, 2020 77:109825
- J Immunol, 2020 ji2000703
- Cancer Manag Res, 2020 12:8413-8424
- Int J Clin Exp Pathol, 2019 12(4):1324-1332
- Hindawi, 2019 15
化学信息&溶解度
分子量 | 404.48 |
分子式 | C20H24N2O5S |
CAS号 | 210826-40-7 |
Smiles | CC(C)(C1=COC(=C1)S(=O)(=O)NC(=O)NC2=C3CCCC3=CC4=C2CCC4)O |
储存条件(自收到货起) | 3年 -20°C 粉状 |
建议分装储备液,避免反复冻融! |
|
体外溶解度 | 批次: |
DMSO : 80 mg/mL ( 197.78 mM; DMSO吸湿会降低化合物溶解度,请使用新开封DMSO) Ethanol : 5 mg/mL Water : Insoluble DMSO : 81 mg/mL ( 200.25 mM; DMSO吸湿会降低化合物溶解度,请使用新开封DMSO) Ethanol : 3 mg/mL Water : Insoluble DMSO : 81 mg/mL ( 200.25 mM; DMSO吸湿会降低化合物溶解度,请使用新开封DMSO) Ethanol : 7 mg/mL Water : Insoluble |
体内溶解度 | 批次: |
现配现用,请按从左到右的顺序依次添加,澄清后再加入下一溶剂 | |
5% DMSO
95% Corn oil
浓度:0.35mg/ml
(0.87mM)
操作示例:以1 mL工作液为例,取50μL 7mg/ml的澄清DMSO储备液加到950μL玉米油中,混合均匀。工作液请现配现用!
|
|
5%DMSO
40%PEG300
5%Tween80
50%ddH2O
浓度:4.05mg/ml
(10.01mM)
操作示例:以 1 mL 工作液为例,取50μL81mg/ml的澄清DMSO储备液加到 400μL PEG300中,混合均匀使其澄清;向上述体系中加入50μLTween80,混合均匀使其澄清;然后继续加入500μL ddH2O定容至 1 mL。工作液请现配现用!
|
|
5%DMSO
40%PEG300
5%Tween80
50%ddH2O
浓度:2.5mg/ml
(6.18mM)
操作示例:以 1 mL 工作液为例,取50μL50mg/ml的澄清DMSO储备液加到400μL PEG300中,混合均匀使其澄清;向上述体系中加入50μLTween80,混合均匀使其澄清;然后继续加入500μL ddH2O定容至 1 mL。工作液请现配现用!
|
摩尔浓度计算器
质量(g)= 浓度(mol/L)* 体积(L)* 分子量(g/mol)
动物体内配方计算器(澄清溶液)
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系Selleck为您提供正确的澄清溶液配方)
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,注:如该浓度超过该批次药物DMSO溶解度,请先联系Selleck);
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入 μL Tween 80,混匀澄清后加入 μL ddH2O,混匀澄清。
体内配方配制方法:取 μL DMSO母液,加入 μL Corn oil,混匀澄清。
注意:
1. 首先保证母液是澄清的;
2.一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。